Administration of CTLA4 mAb blocks the immunosuppressive mechanism of gMDSCs as well as Treg cells within the tumor microenvironment in MOC1 tumors [25], which may further confer therapeutic benefits. This evidence concerns the gene CTLA4 and neoplasm.